Medical Chronicle November/December 2013 | Page 39

New
When science and
technology meet.
Xefo®rapid is a tablet with a delivery method
that has comparable pharmacokinetics to an
intramuscular injection,1 resulting in rapid relief
from pain and inflammation 2, 3
•
•
•
•

Effective relief of pain and inflammation 2, 3
Rapid onset of action for effective pain relief
Good tolerability and safety profile 2, 3
Balanced COX-1 and COX-2 4

2

References: 1. Radhofer-Welte S, Dittrich P, Simin M, Branebjerg PE. Comparative Bioavailability of Lornoxicam as Single Doses of Quick-Release Tablet, Standard Tablet and Intramuscular Injection. A randomized,
Open-Label, Crossover Phase I Study in Healthy Volunteers. Clin Drug Invest 2008;28(6):345-351. 2. Møller PL, Nørholt SE. Analgesic Efficacy of Quick-Release versus Standard Lornoxicam for Pain after Third
Molar Surgery. A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Trial. Clin Drug Invest 2008;28(12):757-766. 3. Yakhno N, Guekht A, Skoromets A, Spirin N, Strachunskaya E, Ternavsky A, et al.
Analgesic Efficacy and Safety of Lornoxicam Quick-Release Formulation Compared with Diclofenac Potassium. Randomised, Double-Blind Trial in Acute Low Back Pain. Clin Drug Invest 2006;26(5):267-277.
4. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro.
Inflamm Res 1999;48:369-379.
S3 XEFO® RAPID tablets. Reg. No. 44/3.1/0331. Each film-coated tablet contains 8 mg lornoxicam and is sugar-free. S3 XEFO® 4 mg Tablets. Reg No: 33/3.1/0247. Each film-coated tablet contains 4 mg lornoxicam.
S3 XEFO® 8mg Tablets. Reg No: 33/3.1/0248. Ea